The Brokers Issue Forecasts for Zimmer Biomet Holdings Inc.’s Q1 2017 Earnings (ZBH)

The Brokers Issue Forecasts for Zimmer Biomet Holdings Inc.’s Q1 2017 Earnings (ZBH)

Zimmer Biomet Holdings Inc. (NYSE:ZBH) – Analysts at Leerink Swann cut their Q1 2017 earnings estimates for shares of Zimmer Biomet Holdings in a research report issued on Thursday. Leerink Swann analyst R. Newitter now expects that the firm will post earnings of $2.12 per share for the quarter, down from their prior forecast of $2.15. Leerink Swann has a “Outperform” rating and a $136.00 price objective on the stock. Leerink Swann also issued estimates for Zimmer Biomet Holdings’ Q2 2017 earnings at $2.17 EPS, Q3 2017 earnings at $1.94 EPS, FY2017 earnings at $8.60 EPS and FY2018 earnings at $9.54 EPS.

A number of other research analysts have also weighed in on ZBH. Canaccord Genuity reissued a “buy” rating and set a $130.00 price target (down previously from $150.00) on shares of Zimmer Biomet Holdings in a research note on Monday, October 31st. Jefferies Group reduced their price target on Zimmer Biomet Holdings from $150.00 to $129.00 and set a “buy” rating on the stock in a research note on Tuesday, November 1st. Needham & Company LLC raised Zimmer Biomet Holdings from a “buy” rating to a “strong-buy” rating and cut their target price for the stock from $150.00 to $148.00 in a research report on Tuesday, November 1st. Royal Bank Of Canada cut their target price on Zimmer Biomet Holdings from $143.00 to $130.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 1st. Finally, RBC Capital Markets reaffirmed an “outperform” rating and issued a $130.00 target price (down from $143.00) on shares of Zimmer Biomet Holdings in a research report on Tuesday, November 1st. Four research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $130.45.

Zimmer Biomet Holdings (NYSE:ZBH) opened at 113.65 on Monday. Zimmer Biomet Holdings has a 52-week low of $88.27 and a 52-week high of $133.21. The stock’s 50 day moving average price is $104.68 and its 200 day moving average price is $118.26. The firm has a market capitalization of $22.76 billion, a PE ratio of 63.63 and a beta of 1.23.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.79. The business earned $1.83 billion during the quarter, compared to analysts’ expectations of $950.20 million. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.64 EPS.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 27th. Stockholders of record on Friday, December 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Wednesday, December 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.84%. Zimmer Biomet Holdings’s dividend payout ratio is presently 75.00%.

In other news, insider David A. Jr. Nolan sold 5,050 shares of the firm’s stock in a transaction dated Friday, December 2nd. The stock was sold at an average price of $101.11, for a total transaction of $510,605.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.22% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Cohen & Steers Inc. increased its stake in shares of Zimmer Biomet Holdings by 2,057.7% in the second quarter. Cohen & Steers Inc. now owns 2,814,345 shares of the company’s stock valued at $60,874,000 after buying an additional 2,683,915 shares in the last quarter. Winslow Capital Management LLC acquired a new stake in shares of Zimmer Biomet Holdings during the second quarter valued at $310,013,000. Ameriprise Financial Inc. increased its stake in shares of Zimmer Biomet Holdings by 38.9% in the second quarter. Ameriprise Financial Inc. now owns 4,853,226 shares of the company’s stock valued at $584,179,000 after buying an additional 1,359,249 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Zimmer Biomet Holdings by 8.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 17,028,139 shares of the company’s stock valued at $2,049,848,000 after buying an additional 1,340,461 shares in the last quarter. Finally, BlackRock Advisors LLC increased its stake in shares of Zimmer Biomet Holdings by 112.1% in the second quarter. BlackRock Advisors LLC now owns 2,445,287 shares of the company’s stock valued at $294,364,000 after buying an additional 1,292,182 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Related posts

Leave a Comment